We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+9%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$66.4M
(+54%)
Cap. Flow
+$55.9M
Cap. Flow
% of AUM
29.6%
Top 10 Holdings %
Top 10 Hldgs %
83.98%
Holding
25
New
6
Increased
11
Reduced
1
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$23.9M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$18.5M |
| 3 |
Sanofi
SNY
|
+$17M |
| 4 |
AGN
Allergan Inc
AGN
|
+$6.32M |
| 5 |
Biogen
BIIB
|
+$5.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$15.2M |
| 2 |
Viatris
VTRS
|
+$12.8M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$5.76M |
| 4 |
Cooper Companies
COO
|
+$4.75M |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
+$4.46M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.73% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$448B
| $24.3M | 12.89% |
+473,700
| New | +$23.9M |
|
|
2
Sanofi
SNY
$105B
| $23.7M | 12.53% |
452,600
+335,600
| +287% | +$17M |
|
3
Teva Pharmaceuticals
TEVA
$36.1B
| $23.3M | 12.32% |
440,400
+95,100
| +28% | +$4.4M |
|
|
MDVN
4
DELISTED
MEDIVATION, INC.
MDVN
| $16.2M | 8.56% |
+502,200
| New | +$18.5M |
|
5
Amgen
AMGN
$197B
| $15.8M | 8.37% |
128,098
+44,298
| +53% | +$5.37M |
|
6
Community Health Systems
CYH
$440M
| $15.5M | 8.22% |
479,644
+124,388
| +35% | +$4.11M |
|
7
Orthofix Medical
OFIX
$467M
| $15M | 7.97% |
499,098
+18,298
| +4% | +$422K |
|
|
AGN
8
DELISTED
Allergan Inc
AGN
| $12.4M | 6.56% |
99,800
+51,900
| +108% | +$6.32M |
|
9
Cardinal Health
CAH
$52.9B
| $6.24M | 3.3% |
89,100
+19,700
| +28% | +$1.37M |
|
|
MGLN
10
DELISTED
Magellan Health Services, Inc.
MGLN
| $6.14M | 3.25% |
103,400
+41,300
| +67% | +$2.46M |
|
|
WCG
11
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.66M | 3% |
+89,100
| New | +$5.78M |
|
12
Enanta Pharmaceuticals
ENTA
$383M
| $5.64M | 2.99% |
141,128
-19,343
| -12% | -$703K |
|
|
13
Biogen
BIIB
$29.5B
| $5.57M | 2.95% |
+18,200
| New | +$5.78M |
|
|
XNPT
14
DELISTED
XENOPORT, INC.
XNPT
| $4.07M | 2.16% |
787,600
+545,800
| +226% | +$3.29M |
|
|
KYTH
15
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $3.56M | 1.88% |
89,500
+10,500
| +13% | +$470K |
|
|
SGNT
16
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $3.16M | 1.68% |
+135,400
| New | +$2.96M |
|
17
Rigel Pharmaceuticals
RIGL
$734M
| $1.64M | 0.87% |
42,140
+30,170
| +252% | +$1.08M |
|
|
FPRX
18
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $958K | 0.51% |
+48,700
| New | +$827K |
|
|
19
Cooper Companies
COO
$14B
| – | – |
-153,600
| Closed | -$4.75M |
|
20
Edwards Lifesciences
EW
$48.9B
| – | – |
-244,200
| Closed | -$2.68M |
|
|
21
GSK
GSK
$100B
| – | – |
-228,480
| Closed | -$15.2M |
|
|
22
Ironwood Pharmaceuticals
IRWD
$634M
| – | – |
-458,735
| Closed | -$4.46M |
|
|
NVO
23
Novo Nordisk
NVO
$219B
| – | – |
-312,000
| Closed | -$5.76M |
|
|
24
Viatris
VTRS
$19.8B
| – | – |
-294,500
| Closed | -$12.8M |
|
|
AET
25
DELISTED
Aetna Inc
AET
| – | – |
-26,300
| Closed | -$1.8M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q1 2014 Portfolio in Review
As of Q1 2014, Senzar Asset Management held 25 positions worth $189M, up 54% from $122M the previous quarter. Its ten largest holdings account for 84% of the portfolio.
Senzar Asset Management deployed $55.9M of net new capital in Q1 2014, opening 6 new positions and adding to 11 existing holdings. Its largest new stake was AbbVie: 473,700 shares worth $24.3M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 95% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Enanta Pharmaceuticals, an estimated $703K trimmed.
- Senzar Asset Management's largest Q1 2014 buy was AbbVie: 473,700 shares worth $24.3M.
- Senzar Asset Management added most to Sanofi in Q1 2014, an estimated $17M increase.
- Senzar Asset Management's biggest Q1 2014 reduction was Enanta Pharmaceuticals, cutting an estimated $703K.
- Senzar Asset Management fully exited GSK in Q1 2014, selling an estimated $15.2M.
- Senzar Asset Management's ten largest holdings make up 84% of its $189M portfolio in Q1 2014.
- Senzar Asset Management opened 6 new positions and closed 7 in Q1 2014.
- Senzar Asset Management's portfolio value rose 54% quarter-over-quarter to $189M.
Based on Senzar Asset Management's 13F filing for Q1 2014, filed 15 May 2014.